U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07005687) titled 'Using MSCs for Chronic Active Antibody Mediated Rejection' on May 29, 2024.
Brief Summary: Mesenchymal stem cell (MSCs) therapy has already been studied in kidney transplant recipients (KTRs), and the available data showed that it is safe and well tolerated. The aim of this study was to evaluate the safety and efficacy of autologous MSCs in combination with standard therapy in KTRs with biopsy-proven chronic active antibody-mediated rejection (AMR). Patients with biopsy-proven chronic active AMR received treatment with autologous bone marrow-derived MSCs (3 x 106 cells/kg iv) after completion of standard therapy and were followed for...